Inceptionr LLC Raises Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Inceptionr LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 32.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 17,143 shares of the biopharmaceutical company’s stock after acquiring an additional 4,192 shares during the period. Inceptionr LLC’s holdings in Gilead Sciences were worth $1,583,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. State Street Corp raised its position in Gilead Sciences by 1.4% in the 3rd quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock worth $5,044,795,000 after buying an additional 841,776 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Gilead Sciences by 50.9% during the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock valued at $2,900,921,000 after purchasing an additional 11,665,593 shares during the last quarter. FMR LLC increased its position in shares of Gilead Sciences by 79.4% during the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after purchasing an additional 14,680,161 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Gilead Sciences by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock valued at $2,302,119,000 after purchasing an additional 574,421 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Gilead Sciences by 3.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 8,002,779 shares of the biopharmaceutical company’s stock valued at $739,217,000 after purchasing an additional 249,804 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on GILD. BMO Capital Markets upped their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. JPMorgan Chase & Co. upped their price target on Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Oppenheimer increased their target price on Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a research report on Tuesday. Piper Sandler increased their price target on Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Finally, Morgan Stanley increased their price target on Gilead Sciences from $113.00 to $123.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $104.24.

Gilead Sciences Trading Up 0.6 %

Shares of GILD opened at $115.44 on Thursday. The stock’s 50-day moving average is $98.71 and its two-hundred day moving average is $90.91. The stock has a market cap of $143.87 billion, a PE ratio of 312.00, a P/E/G ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $117.39. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 2.74%. Gilead Sciences’s dividend payout ratio (DPR) is 854.05%.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders have sold 293,356 shares of company stock worth $29,166,240. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.